As mutation frequency of the mTOR pathway in HCC patients is about 50%, the mTORi therapy is not appropriate for all, and it’s necessary to identify the mutation status of the mTOR pathway in HCC patients before mTORi application. Here, MTOR is linked to hepatocellular carcinoma.